HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction

HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数

基本信息

  • 批准号:
    9252549
  • 负责人:
  • 金额:
    $ 58.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Funding opportunity HL-132 provides a mechanism to address the condition of heart failure with preserved ejection fraction (HFpEF), which afflicts millions of older Americans and is associated with exercise intolerance, reduced quality of life (QOL), high health care costs, and increased mortality. People with HFpEF display increased cardiac filling pressures and inadequate cardiac output reserve to deliver blood to the body during exercise. Numerous lines of evidence have implicated abnormalities in nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling as playing a key role in promoting these abnormalities. While there is currently no proven effective medical treatment for HFpEF, exercise training (ET) has been shown to improve aerobic ca- pacity and QOL in this population. However, ET provides benefits through peripheral effects without targeting the cardiac limitations. The long-term goal of this research is to identify novel treatments for HFpEF based upon detailed understanding of its pathophysiology. The specific objectives of this application are to determine whether treatment with sodium nitrite (NO2-) in addition to ET can improve exercise capacity, chronic activity levels, and QOL in people with HFpEF. The guiding hypothesis is that enhancing NO-cGMP signaling in the heart and periphery preferentially during exercise will improve functional capacity and symptoms in HFpEF above and beyond what is seen with ET alone. Conversion of NO2- to biologically active NO is enhanced during tissue hypoxia and acidosis, which develop during low-level exercise in HFpEF, so it is expected that this intervention will preferentially target the cardiac limitations that develop during exercise i these patients at the time of greatest need. This hypothesis will be tested by pursuing two specific aims: (1) Determine whether treatment with NO2- in addition to ET for 12 weeks improves exercise capacity and hemodynamic reserve in people with HFpEF as compared to placebo with ET, and (2) Determine whether treatment with NO2- in addition to ET for 12 weeks increases chronic daily activity levels and QOL, and reduces symptoms of effort intolerance during ET. Under the first aim, expired gas analysis, inert gas (C2H2) rebreathe and echocardiography will be performed at rest and during exercise to measure oxygen consumption, cardiac output responses and central hemodynamics to maximal effort exercise before and after completion of 12 weeks of ET with NO2- as compared to ET with placebo. Under the second aim, subjects will use externally-worn accelerometer devices to quantify chronic daily physical activity over the 12-week study, QOL will be assessed by questionnaire, and ET tolerability will be measured by perceived effort and dyspnea scores reported during ET sessions. This proposal is innovative and significant because it will allow for greater utilization and enhanced benefit from ET in people with HFpEF by using a novel class of medicine that we have shown to preferentially target cardiac abnormalities developing with exercise in a growing population of older Americans for whom there are few current treatment options available.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barry A. Borlaug其他文献

HEMODYNAMIC RESPONSES TO ARTERIAL VASODILATION FUNDAMENTALLY DIFFER IN HEART FAILURE WITH PRESERVED VERSUS REDUCED EJECTION FRACTION
  • DOI:
    10.1016/s0735-1097(11)60196-4
  • 发表时间:
    2011-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Shmuel Schwartzenberg;Margaret M. Redfield;Aaron M. From;Sorajja Paul;Rick A. Nishimura;Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
The pathophysiology of heart failure with preserved ejection fraction
射血分数保留的心力衰竭的病理生理学
  • DOI:
    10.1038/nrcardio.2014.83
  • 发表时间:
    2014-06-24
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
Impact of Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction
  • DOI:
    10.1016/j.cardfail.2018.07.018
  • 发表时间:
    2018-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Katlyn E. Koepp;Masaru Obokata;Yogesh N. Reddy;Thomas P. Olson;Barry A. Borlaug
  • 通讯作者:
    Barry A. Borlaug
Heart Failure With Preserved Ejection Fraction: emJACC/em Scientific Statement
射血分数保留的心力衰竭:emJACC/em 科学声明
  • DOI:
    10.1016/j.jacc.2023.01.049
  • 发表时间:
    2023-05-09
  • 期刊:
  • 影响因子:
    22.300
  • 作者:
    Barry A. Borlaug;Kavita Sharma;Sanjiv J. Shah;Jennifer E. Ho
  • 通讯作者:
    Jennifer E. Ho
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program
心房颤动与司美格鲁肽在射血分数保留的肥胖相关性心力衰竭中的作用:STEP-HFpEF项目
  • DOI:
    10.1016/j.jacc.2024.08.023
  • 发表时间:
    2024-10-22
  • 期刊:
  • 影响因子:
    22.300
  • 作者:
    Subodh Verma;Javed Butler;Barry A. Borlaug;Melanie J. Davies;Dalane W. Kitzman;Mark C. Petrie;Sanjiv J. Shah;Thomas Jon Jensen;Søren Rasmussen;Cecilia Rönnbäck;Bela Merkely;Evan O’Keefe;Mikhail N. Kosiborod;STEP-HFpEF and STEP-HFpEF DM Investigators
  • 通讯作者:
    STEP-HFpEF and STEP-HFpEF DM Investigators

Barry A. Borlaug的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barry A. Borlaug', 18)}}的其他基金

Pulmonary Hypertension in Left Heart Disease
左心病肺动脉高压
  • 批准号:
    10656879
  • 财政年份:
    2023
  • 资助金额:
    $ 58.75万
  • 项目类别:
Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
  • 批准号:
    10679096
  • 财政年份:
    2021
  • 资助金额:
    $ 58.75万
  • 项目类别:
Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
  • 批准号:
    10323121
  • 财政年份:
    2021
  • 资助金额:
    $ 58.75万
  • 项目类别:
Mayo Clinic HeartShare Clinical Center
梅奥诊所 HeartShare 临床中心
  • 批准号:
    10483137
  • 财政年份:
    2021
  • 资助金额:
    $ 58.75万
  • 项目类别:
HL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection Fraction
HL-无机亚硝酸盐可增强心力衰竭运动训练的益处并保留射血分数
  • 批准号:
    9459406
  • 财政年份:
    2016
  • 资助金额:
    $ 58.75万
  • 项目类别:

相似国自然基金

肿瘤微环境因子Lactic acidosis在肿瘤细胞耐受葡萄糖剥夺中的作用机制研究
  • 批准号:
    81301707
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Identification of factor to induce lactic acidosis in pre-metastatic niche
转移前微环境中诱导乳酸性酸中毒的因素的鉴定
  • 批准号:
    23K06620
  • 财政年份:
    2023
  • 资助金额:
    $ 58.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Carbonic Anhydrase IX Acts as a Novel CO2/HCO3- Sensor and Protects the Pulmonary Endothelial Barrier from Acidosis
碳酸酐酶 IX 作为新型 CO2/HCO3- 传感器并保护肺内皮屏障免受酸中毒的影响
  • 批准号:
    10678442
  • 财政年份:
    2023
  • 资助金额:
    $ 58.75万
  • 项目类别:
Investigation based on both basic and clinical study about acidosis caused by piganide, SGLT2 inhibitor and surgical stress
皮甘尼、SGLT2抑制剂和手术应激引起的酸中毒的基础和临床研究
  • 批准号:
    23K08372
  • 财政年份:
    2023
  • 资助金额:
    $ 58.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of proton-sensing G-protein-coupled receptors in the regulation of microglia and microvessel endothelial cell function in brain acidosis in a mouse ischemia reperfusion model.
质子感应 G 蛋白偶联受体在小鼠缺血再灌注模型脑酸中毒中调节小胶质细胞和微血管内皮细胞功能的作用。
  • 批准号:
    22K07342
  • 财政年份:
    2022
  • 资助金额:
    $ 58.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Magnetic Resonance Fingerprinting of Tumor Vascular Perfusion and Acidosis
肿瘤血管灌注和酸中毒的磁共振指纹图谱
  • 批准号:
    10593285
  • 财政年份:
    2022
  • 资助金额:
    $ 58.75万
  • 项目类别:
Acidosis in pulmonary endothelial injury and repair
酸中毒与肺内皮损伤与修复
  • 批准号:
    10341493
  • 财政年份:
    2022
  • 资助金额:
    $ 58.75万
  • 项目类别:
Acidosis in pulmonary endothelial injury and repair
酸中毒与肺内皮损伤与修复
  • 批准号:
    10558528
  • 财政年份:
    2022
  • 资助金额:
    $ 58.75万
  • 项目类别:
Characterization of an abundant lactate-utilizing Campylobacter involved in mitigating rumen acidosis
参与减轻瘤胃酸中毒的丰富乳酸利用弯曲杆菌的表征
  • 批准号:
    557929-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 58.75万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney disease
代谢性酸中毒对慢性肾病患者肌肉线粒体能量学、代谢健康和身体耐力的影响
  • 批准号:
    10278747
  • 财政年份:
    2021
  • 资助金额:
    $ 58.75万
  • 项目类别:
Impact of metabolic acidosis on muscle mitochondrial energetics, metabolic health and physical endurance in persons with chronic kidney disease
代谢性酸中毒对慢性肾病患者肌肉线粒体能量学、代谢健康和身体耐力的影响
  • 批准号:
    10671682
  • 财政年份:
    2021
  • 资助金额:
    $ 58.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了